rabacfosadine
Small moleculeexperimental
Rabacfosadine, sold under the brand name Tanovea, is a guanine nucleotide analog used for the treatment of lymphoma in dogs. It was developed by Gilead Sciences as GS-9219. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2007 (NCT00499239)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- DNA polymerase nuINHIBITOR
POLN inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)[C@H](C)NP(=O)(COCCn1cnc2c(NC3CC3)nc(N)nc21)N[C@@H](C)C(=O)OCC- Mol. weight
- 526.54 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- WikipediaRabacfosadine ↗
- ChEMBLCHEMBL1823518 ↗
Also known as
- gs-9219
- gs-9219
- gs-9219
- rabacfosadine
- rabacfosadine
- rabacfosadine
- vdc-1101
- vdc-1101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00499239 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2007 | Gilead Sciences |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gilead Sciences | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1